Physician profile
Robert N Ulseth
NPI 1043205305
$1,548.48
in general payments reported to CMS, 2019-2025
25 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $216 · 2021: $256 · 2022: $276 · 2023: $302 · 2024: $114 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $519.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $787.40 | 2019-2025 | Xtampza |
| Protega Pharmaceutials INC | $160.70 | 2022-2023 | Roxybond |
| Otsuka America Pharmaceutical, INC. | $72.42 | 2021-2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $69.41 | 2024-2025 | Caplyta |
| Grt US Holding, INC. | $68.81 | 2021-2022 | |
| Abbvie INC. | $68.59 | 2022-2023 | Qulipta, Ubrelvy |
| Redhill Biopharma INC. | $33.39 | 2020-2022 | |
| Pfizer INC. | $28.60 | 2023-2024 | |
| Vertex Pharmaceuticals Incorporated | $27.92 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $23.31 | 2022 | |
| Si-Bone, INC. | $17.16 | 2025 | |
| Kaleo, INC. | $16.45 | 2019 | |
| Amgen INC. | $15.93 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.93 | 2021 | |
| Tonix Medicines, INC. | $14.79 | 2025 | Tonmya |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Flowonix Medical Incorporated | $14.78 | 2019 | |
| Medtronic, INC. | $14.42 | 2022 | |
| Boston Scientific Corporation | $14.37 | 2019 | |
| Lilly USA, LLC | $13.41 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.25 | 2019 | |
| Zyla Life Sciences, INC. | $12.12 | 2019 | |
| Eisai INC. | $12.03 | 2021 | |
| Biodelivery Sciences International, INC. | $11.62 | 2019 | |
| Indivior INC. | $10.94 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ulseth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.